TransTissue transfers theory to clinical practice.



TransTissue, founded as a spin-off of the University Hospital Charité in February 2000, has been a subsidiary of BioTissue Technologies, Freiburg since September 2001.

With more than 15 years of experience in the field of tissue engineering and regenerative medicine, the scientists and founders of TransTissue have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts and innovative third-generation cell-free cartilage implants.

As a technology company, we focus on inventions and the development of products and treatment strategies in regenerative medicine.

Tissue Engineering

Promising new biological technologies in regenerative medicine address cell-based and cell-free approaches by using/mobilizing autologous cells in supportive carrier matrices and the controlled application of growth factors to promote the development of new tissue, such as cartilage or bone.

Common principles in regenerative medicine thus focus on the following essential components: cells, which have to be easy to achieve and have a high differentiation potential, an appropriate carrier for transplantation and/or implantation, and a set of defined bioactive molecules driving the process of tissue formation and maturation.

Our goal is to transfer theory to clinical practice.


Beyond the mission of our scientific team to develop therapeutic products for regenerative medicine as well as innovative cell and tissue platform technologies, we are committed to the refinement of existing and the development of new strategies for tissue regeneration.

With knowledge of the requirements and in cooperation with our clinical partners, TransTissue develops treatment strategies and products which can easily be implemented in clinical practice.

Focusing on the 2nd and 3rd generations of soft and hard tissue repair, TransTissue has developed novel and innovative cell-based transplants and cell-free implants.

Cell-based applications spotlight therapies for osteoarthritic cartilage and jawbone defects and are based on autologous mesenchymal cells. Cell-free applications are based on the recruitment of mesenchymal stem and progenitor cells to a defective site and their guidance to regenerate this tissue.

Finally, with our in vitro model of rheumatoid arthritis (“pannus model”), we are enhancing a test system aimed at high-throughput screening of anti-rheumatic candidate drugs.

GMP Compliance

TransTissue rapidly transfers laboratory processes to standardized and controlled procedures to produce tissue engineering and advanced therapy medicinal products and medical devices in compliance with GMP guidelines.

Two medicinal products, BioSeed®-C and chondrotissue® developed by TransTissue and authorized for clinical use, are produced and distributed by BioTissue.

BioSeed®-C is an autologous 3D chondrocyte graft used to treat articular cartilage defects. Chondrotissue® is a CE-marked cell-free matrix for treatment of cartilage in microfracture.

The products are manufactured in GMP laboratories in compliance with European legislation and subject to the stringent requirements of component authorities.